Premium
Effect of enalaprilat on bradykinin and des‐Arg 9 ‐bradykinin release following reperfusion of the ischaemic rat heart
Author(s) -
Lamontagne Daniel,
Nadeau Réginald,
Adam Albert
Publication year - 1995
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1995.tb16357.x
Subject(s) - enalaprilat , bradykinin , chemistry , medicine , endocrinology , angiotensin ii , angiotensin converting enzyme , metabolite , ace inhibitor , blood pressure , receptor
1 The release of bradykinin (BK) and its metabolite, des‐Arg 9 ‐bradykinin (des‐Arg 9 ‐BK), was studied following reperfusion of a globally ischaemic rat heart. 2 BK‐like immunoreactivity increased from 13±3 (preischaemic value) to 48±12 fmol min −1 g −1 ( P <0.05, n = 14) 30 s after reperfusion. No difference in BK release was found between control hearts and hearts pretreated with the angiotensin converting enzyme (ACE or kininase II) inhibitor, enalaprilat (50 ng ml −1 ). 3 No significant change in des‐Arg 9 ‐BK‐like immunoreactivity during reperfusion was observed in control hearts. In contrast, des‐Arg 9 ‐ BK ‐ like immunoreactivity rose from 44 ± 15 to 177 ± 61 fmol min −1 g −1 ( P <0.05, n = 7) 30 s after reperfusion in enalaprilat‐treated hearts. 4 In conclusion, BK is released upon reperfusion of the globally ischaemic rat heart. ACE inhibitors, through the inhibition of kininase II, increase the formation of the active metabolite, des‐Arg 9 ‐BK.